Umhlahlandlela Wakho Oyisisekelo ku-NLPHL kusuka kuma-Symptomes kuya ku-Treatment
I-lodphocyte engavamile ye-Hodgkin lymphoma (i-NLPHL) uhlobo lwesifo se- Hodgkin , umdlavuza wamangqamuzana angama-lymph . Ngenye yezinhlobo ezincane kakhulu ze-Hodgkin lymphoma , equkethe cishe ama-5% kuwo wonke amacala alo mdlavuza. Kodwa-ke, inezici eziningana ezihlukile ezazihlukanisa nezinye izinhlobo ze-Hodgkin isifo esibizwa ngokuthi i-classical Hodgkin lymphomas.
Ubani Othola I-Lymphocyte Nodular Predominant Hodgkin Lymphoma?
I-NLPHL ingenzeka kunanoma yisiphi isigaba, nakuba iziguli eziningi zivame ukuba zintathu. Kuphindwe kathathu ngokwengeziwe kubantu besilisa uma kuqhathaniswa nesilinganiso sabesifazane. Ayikho imbangela eqondile, kodwa izici zokufaka ingozi zihlanganisa ukutheleleka ngegciwane lesifo se-Epstein-Barr futhi sibe nesihlobo sokuqala ngeHodgkin lympoma.
Ziyini Izimpawu Zakwa-NLPHL?
Isibonakaliso esiqakathekile salesi sifo ukukhuliswa kwama-lymph nodes entanyeni, esifubeni noma emagumbini. Ukubandakanyeka kwamanye ama-lymph nodes noma ezinye izitho akuvamile. Ezinye izimpawu ze-lymphoma zihlanganisa umkhuhlane, ukulahlekelwa isisindo nokujuluka ebusuku. Ukuhlolwa ngokomzimba, umlando wezokwelapha, nokuhlolwa kwegazi kuzokwenziwa.
Ukuxilongwa kwe-lymphoma kwenziwa nge- lymph node biopsy . Uhlobo oluqondile lwe-lymphoma luhlolwe yizivivinyo zamangqamuzana ezingaveza umehluko phakathi kwe-NLPHL nezinye izinhlobo ze-Hodgkin lymphoma.
I-NLPHL ikhiqizwa yi-B-cells ephazamisekile, ngokuvamile evame ukuyingxenye yesimiso somzimba sokuzivikela omzimba esakhiza izifo zokuzivikela. Zinendlela ehlukile yama-antigens e-CD, amaprotheni aphezulu emangqamuzaneni, avumela ukuxilongwa usebenzisa ukuhlaziywa kwezinto ze-biochemical kanye nokuhlolwa kwe-CD marker. Lezi zindlela eziyingqayizivele ze-antigen ze-CD nazo zisetshenziselwa ukwelashwa kwe-monoclonal antibody.
I-NLPHL ithathwa kanjani?
Iziguli ezingaba ngu-8 kwabangu-10 abane-NLPHL zitholakala ukuthi zine- lymphoma esencane ekuqaleni , ezibandakanya i-lymph nodes kuphela entanyeni nengxenye engaphezulu yomzimba. I-NLPHL ijwayele ukukhula ijubane kune-Hodgkin lymphoma yesilasi, futhi uma ungenayo izimpawu kungase kunqunywe ukubuka futhi ulinde izimpawu ngaphambi kokuqala ukwelashwa. Uma i-lymphoma isesimweni sokuqala futhi awunazo izimpawu ze-B zingelashwa nge-radiation therapy kuphela. Izimpawu ze-B zifaka umkhuhlane, ukulahlekelwa isisindo, nokugcoba ukujula ebusuku.
Uma unezimpawu ze-B noma icala lakho lisesimweni esithuthukisiwe kakhulu, ukwelashwa kwe-nodular lymphocyte i-Hodgkin lymphoma ehlanganisa i-chemotherapy futhi ngokuvamile ukwelashwa kwama-radiation kwenziwa. I-antioclonal antibody rituximab inganikwa futhi Iningi leziguli ziphendula kahle kakhulu ekwelapheni, futhi amaphesenti angu-90 aphulukiswa. Izinga lokusinda kwezifo zeHodgkin ziyathuthuka ngenxa yentuthuko ekwelapheni.
Ngenkathi lokhu kuyisibonelo esihle, ku-10% kuya ku-40% weziguli isifo esikhulu se-B-cell lymphoma esingaba seminyaka eyishumi emva kokwelashwa. Njengoba i-NLPHL ivame ukuvela ezinsizweni, kubalulekile ukuthi ziqhubeke zilandelwa isikhathi eside ukuze zithole ukuphindaphindiwe. Ngenkathi ukwelashwa kwabo kokuqala kungase kubonakale kuveze ukwelashwa, ukuphindaphindiwe kokuphindaphindiwe nokuqhubekayo kubalulekile kangangokuthi badinga ukuqapha okuqhubekayo isikhathi eside.
Ukwelashwa kweziguli ze-NLPHL eziphinde zabuyiselwa nge-rituximab, i-antibody monoclonal, iyahlolwa.
Imithombo:
I-Cancer: Izimiso Nokusebenza Kwe-Oncology 7th Edition. Abahleli: VT DeVita, S Hellman noSA Rosenberg. Ishicilelwe nguLippincott Williams noWilkins, ngo-2005.
> I-National Cancer Insit. I-Adult Hodgkin Lymphoma Treatment-yezokwelapha (PDQ®).
> I-American Cancer Society. Ukwelapha i-nodular lymphocyte isifo esikhulu se-Hodgkin (NLPHD).